XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. It demonstrates significant anti-proliferative activity along with excellent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). XmAb-2513 is applicable in research on hematological malignancies such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL).
Target:
TNF
* VAT and and shipping costs not included. Errors and price changes excepted
